Irbesartan Dawa (Irbesartan)

Irbesartan belongs to the angiotensin II receptor blocker class and is used to manage conditions related to the renin‑angiotensin system.

• Hypertension: lowers elevated blood pressure and reduces cardiovascular risk.
• Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes.
• Proteinuria associated with hypertension: decreases urinary protein excretion, helping preserve renal function.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal cells. By preventing angiotensin II binding, it inhibits vasoconstriction and aldosterone secretion, leading to reduced peripheral resistance, lower blood volume, and ultimately a decrease in systemic blood pressure.

Irbesartan is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or weak.
• Nausea: upset stomach or urge to vomit.
• Abdominal pain: discomfort in the stomach area.
• Back pain: soreness in the lower back.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing.
• Hyperkalemia: elevated potassium levels that can affect heart rhythm.
• Acute kidney injury: sudden decline in renal function.
• Hepatic injury: signs of liver damage such as jaundice.
• Severe hypotension: markedly low blood pressure causing faintness.
• Allergic rash: widespread skin eruption or hives.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal function monitoring: assess serum creatinine and eGFR regularly.
• Electrolyte assessment: check potassium levels to detect hyperkalemia.
• Hepatic impairment: use caution in patients with severe liver disease.
• Pregnancy and lactation: avoid use during pregnancy; discontinue if pregnancy is confirmed.
• Drug discontinuation: taper or stop under medical supervision to prevent rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia.
• Aliskiren (in diabetic patients): may increase renal adverse events.
• ACE inhibitors: combined use can cause excessive potassium rise and renal dysfunction.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair kidney function.
• Lithium: increased lithium levels, risk of toxicity.
• Cyclosporine or tacrolimus: may elevate serum creatinine.
• Diuretics: may enhance hypotensive effect; monitor blood pressure.